A possible treatment for severe Covid "puts patients at risk for no clear benefit", a trial found.

More than 1,000 people took part in the UK-wide trial of the blood thinner Apixaban while in hospital with Covid.

The Addenbrooke's Hospital and University of Cambridge study aims to find a treatment to prevent death from Covid, and readmission to hospital.

It found the drug had no impact, but some patients did experience side effects including major bleeding.

Dr Mark Toshner, joint chief investigator for the trial, said it had been assumed that Apixaban could help patients recover from severe Covid.

"This trial is the first robust evidence that longer anticoagulation after acute Covid-19 puts patients at risk for no clear benefit," he said.

"Our hope is that these results will stop this drug being needlessly prescribed to patients with Covid-19 and we can change medical practice."


[link to www.bbc.co.uk (secure)]


They are really panicking now.